Compare BigBearai Holdings Inc (BBAI) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs BioNTech SE - ADR — how do they compare? BigBearai Holdings Inc trades at $3.26 (market cap $1.60B), while BioNTech SE - ADR trades at $92.94 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 14.6× BigBearai Holdings Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBAI | BNTX | |
|---|---|---|
Market Cap | $1.60B | $23.31B |
Sector | Technology | Health |
52-Week High | $8.91 | $119.34 |
52-Week Low | $2.61 | $83.89 |
Enterprise Value | $1.30B | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BigBear.ai (BBAI) trades at $3.25, up 0.62% with a bullish technical signal. The company reported Q2 2026 revenue growth of 13% and margin expansion but missed EPS expectations. With a P/S ratio of 11.31 and negative profitability metrics, the stock faces fundamental challenges despite recent contract wins and product innovation in defense AI solutions.
Outlook remains cautious with persistent losses and cash burn offset by government contract momentum. Investment opportunity lies in defense AI specialization, while risks include execution challenges and competitive pressures. Analyst consensus shows 75% hold rating, reflecting balanced skepticism about near-term profitability.
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
